ZULRESSO
Total Payments
$5.1M
Transactions
3,910
Doctors
2,208
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $561,933 | 15 | 10 |
| 2023 | $489,102 | 645 | 509 |
| 2022 | $1.4M | 1,377 | 962 |
| 2021 | $1.3M | 902 | 642 |
| 2020 | $1.2M | 548 | 305 |
| 2019 | $229,032 | 423 | 348 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.6M | 213 | 89.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $169,988 | 97 | 3.3% |
| Consulting Fee | $167,311 | 94 | 3.3% |
| Royalty or License | $83,353 | 8 | 1.6% |
| Food and Beverage | $78,503 | 3,368 | 1.5% |
| Travel and Lodging | $37,709 | 122 | 0.7% |
| Education | $420.00 | 8 | 0.0% |
Payments by Type
Research
$4.6M
213 transactions
General
$537,283
3,697 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF BREXANOLONE IN THE TREATMENT OF ADOLESCENT FEMALE SUBJECTS WITH POSTPARTUM DEPRESSION | Sage Therapeutics, Inc. | $890,069 | 2 |
| A STUDY OF BREXANOLONE FOR ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 | Sage Therapeutics, Inc. | $560,137 | 3 |
| Brexanolone injection for Postpartum Psychosis | Sage Therapeutics, Inc. | $490,713 | 0 |
| A STUDY TO ASSESS THE SAFE-USE CONDITIONS FOR ADMINISTRATION OF ZULRESSO IN A HOME SETTING | Sage Therapeutics, Inc. | $485,203 | 0 |
| Brexanolone injection for postpartum psychosis | Sage Therapeutics, Inc. | $476,800 | 0 |
| An Open Label Pilot Study of IV Brexanolone for the treatment of Post-Traumatic Stress Disorder | Sage Therapeutics, Inc. | $238,400 | 0 |
| Using Allopregnanolone to Probe Behavioral and Neurobiological Mechanisms that Underlie Depression in Women across Perimenopausal Stage | Sage Therapeutics, Inc. | $238,400 | 0 |
| Mechanism(s) of Neurosteroid-mediated Inhibition of TLR | Sage Therapeutics, Inc. | $181,410 | 0 |
| Utility of Brexanolone to target stress-induced alcohol use among men and women with Posttraumatic Stress Disorder | Sage Therapeutics, Inc. | $178,800 | 0 |
| A Multicenter, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Brexanolone in the Treatment of Adolescent Female Subjects with Postpartum Depression | Sage Therapeutics, Inc. | $167,067 | 0 |
| Pregnancy Registry for Psychiatric Medications | Sage Therapeutics, Inc. | $99,714 | 0 |
| Open Label Study of the Efficacy, Safety and Tolerability of Zulresso in the Treatment of Adult Women with Postpartum Psychosis | Sage Therapeutics, Inc. | $94,545 | 0 |
| Dynamic neural mechanisms of brexanolone-induced antidepressant effects in postpartum depression | Sage Therapeutics, Inc. | $39,953 | 0 |
| AN EVALUATION OF MULTIMODAL NEUROIMAGING PARAMETERS IN WOMEN WITH POSTPARTUM DEPRESSION WHO ARE RECEIVING ZULRESSO | Sage Therapeutics, Inc. | $6,000 | 0 |
| A STUDY TO EVALUATE EFFICACY AND SAFETY OF SAGE-547 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION | Sage Therapeutics, Inc. | $3,060 | 0 |
Top Doctors Receiving Payments for ZULRESSO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Ashley Easterwood | — | Lubbock, TX | $4.7M | 206 |
| , M.D | Obstetrics & Gynecology | Miami, FL | $40,941 | 60 |
| , M.D | Gynecologic Oncology | Harrisburg, PA | $40,544 | 45 |
| , MD, MPH, PA | Obstetrics & Gynecology | League City, TX | $39,656 | 74 |
| , MD,PHD | Psychiatry | Atlanta, GA | $20,000 | 2 |
| , M.D | Obstetrics & Gynecology | Springfield, OR | $14,739 | 32 |
| , M.D | Psychiatry | Costa Mesa, CA | $14,182 | 14 |
| , MD | Critical Care Medicine | Chicago, IL | $12,575 | 13 |
| , MD | Psychiatry | Chapel Hill, NC | $12,375 | 2 |
| , M.D | Psychiatry | New York, NY | $11,958 | 14 |
| , M.D | Psychiatry | Chicago, IL | $10,000 | 1 |
| , M.D | Neurology | Washington, DC | $10,000 | 1 |
| , MD | Psychiatry | Moosic, PA | $9,429 | 10 |
| , MD | Psychiatry | Tampa, FL | $9,315 | 11 |
| , MD | Psychiatry | Charleston, SC | $8,588 | 6 |
| , MD | Psychiatry | Glen Oaks, NY | $8,415 | 6 |
| , M.D | Psychiatry | Baltimore, MD | $7,991 | 8 |
| , MD | Neurology | Long Beach, CA | $7,852 | 9 |
| , MD | Obstetrics & Gynecology | Owensboro, KY | $7,791 | 7 |
| , MD | Psychiatry | Moore, OK | $7,088 | 13 |
| , D.O., PH.D | Psychiatry | Saint Louis, MO | $6,713 | 7 |
| , M.D | Psychiatry | Irvine, CA | $6,705 | 7 |
| , MD | Maternal & Fetal Medicine | Scottsdale, AZ | $6,000 | 2 |
| , MD | Obstetrics & Gynecology | Long Branch, NJ | $5,890 | 6 |
| , MD | Psychosomatic Medicine | Phoenix, AZ | $5,040 | 1 |
Ad
Manufacturing Companies
- Sage Therapeutics, Inc. $5.1M
Product Information
- Type Drug
- Total Payments $5.1M
- Total Doctors 2,208
- Transactions 3,910
About ZULRESSO
ZULRESSO is a drug associated with $5.1M in payments to 2,208 healthcare providers, recorded across 3,910 transactions in the CMS Open Payments database. The primary manufacturer is Sage Therapeutics, Inc..
Payment data is available from 2019 to 2024. In 2024, $561,933 was paid across 15 transactions to 10 doctors.
The most common payment nature for ZULRESSO is "Unspecified" ($4.6M, 89.5% of total).
ZULRESSO is associated with 15 research studies, including "A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF BREXANOLONE IN THE TREATMENT OF ADOLESCENT FEMALE SUBJECTS WITH POSTPARTUM DEPRESSION" ($890,069).